NK Cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT

Justyna Kanold; Catherine Paillard; Andrei Tchirkov; Peter Lang; Antony Kelly; Pascale Halle; Florentina Isfan; Etienne Merlin; Aurelien Marabelle; Emmanuelle Rochette; François Deméocq

doi:10.1002/pbc.24030

NK Cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT

Justyna Kanold, Catherine Paillard, Andrei Tchirkov, Peter Lang, Antony Kelly, Pascale Halle, Florentina Isfan, Etienne Merlin, Aurelien Marabelle, Emmanuelle Rochette, François Deméocq

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

28 Citations (Scopus)

Résumé

Little is known on strategies to prevent or to treat relapses occurring after haploidentical stem cell transplantation (haplo-HSCT) performed for the high-risk neuroblastoma (NB). We describe a 6-year-old male with refractory NB who relapsed 22 months after haplo-HSCT. A complete remission was obtained with a combination of immuno-chemotherapy based on donor NK cells transplants, IL2 infusions and temozolomide/topotecan. This case is an incentive to explore both the immediate therapeutic effect of haplo-graft provided via haplo-NK cells and the immunogenic platform that haplo-HSCT offers for future treatment. Our post-relapse strategy shows that chemo- and bio-treatment should be viewed as complementary therapeutic options. Pediatr Blood Cancer 2012;59:739-742.

langue originale	Anglais
Pages (de - à)	739-742
Nombre de pages	4
journal	Pediatric Blood and Cancer
Volume	59
Numéro de publication	4
Les DOIs	https://doi.org/10.1002/pbc.24030
état	Publié - 1 oct. 2012
Modification externe	Oui

Accès au document

10.1002/pbc.24030

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{9596539087bb422cb8b48aa43705342f,

title = "NK Cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT",

abstract = "Little is known on strategies to prevent or to treat relapses occurring after haploidentical stem cell transplantation (haplo-HSCT) performed for the high-risk neuroblastoma (NB). We describe a 6-year-old male with refractory NB who relapsed 22 months after haplo-HSCT. A complete remission was obtained with a combination of immuno-chemotherapy based on donor NK cells transplants, IL2 infusions and temozolomide/topotecan. This case is an incentive to explore both the immediate therapeutic effect of haplo-graft provided via haplo-NK cells and the immunogenic platform that haplo-HSCT offers for future treatment. Our post-relapse strategy shows that chemo- and bio-treatment should be viewed as complementary therapeutic options. Pediatr Blood Cancer 2012;59:739-742.",

keywords = "Graft-versus-tumour effect, HSCT, NK cells, Neuroblastoma",

author = "Justyna Kanold and Catherine Paillard and Andrei Tchirkov and Peter Lang and Antony Kelly and Pascale Halle and Florentina Isfan and Etienne Merlin and Aurelien Marabelle and Emmanuelle Rochette and Fran{\c c}ois Dem{\'e}ocq",

year = "2012",

month = oct,

day = "1",

doi = "10.1002/pbc.24030",

language = "English",

volume = "59",

pages = "739--742",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

number = "4",

}

TY - JOUR

T1 - NK Cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT

AU - Kanold, Justyna

AU - Paillard, Catherine

AU - Tchirkov, Andrei

AU - Lang, Peter

AU - Kelly, Antony

AU - Halle, Pascale

AU - Isfan, Florentina

AU - Merlin, Etienne

AU - Marabelle, Aurelien

AU - Rochette, Emmanuelle

AU - Deméocq, François

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Little is known on strategies to prevent or to treat relapses occurring after haploidentical stem cell transplantation (haplo-HSCT) performed for the high-risk neuroblastoma (NB). We describe a 6-year-old male with refractory NB who relapsed 22 months after haplo-HSCT. A complete remission was obtained with a combination of immuno-chemotherapy based on donor NK cells transplants, IL2 infusions and temozolomide/topotecan. This case is an incentive to explore both the immediate therapeutic effect of haplo-graft provided via haplo-NK cells and the immunogenic platform that haplo-HSCT offers for future treatment. Our post-relapse strategy shows that chemo- and bio-treatment should be viewed as complementary therapeutic options. Pediatr Blood Cancer 2012;59:739-742.

AB - Little is known on strategies to prevent or to treat relapses occurring after haploidentical stem cell transplantation (haplo-HSCT) performed for the high-risk neuroblastoma (NB). We describe a 6-year-old male with refractory NB who relapsed 22 months after haplo-HSCT. A complete remission was obtained with a combination of immuno-chemotherapy based on donor NK cells transplants, IL2 infusions and temozolomide/topotecan. This case is an incentive to explore both the immediate therapeutic effect of haplo-graft provided via haplo-NK cells and the immunogenic platform that haplo-HSCT offers for future treatment. Our post-relapse strategy shows that chemo- and bio-treatment should be viewed as complementary therapeutic options. Pediatr Blood Cancer 2012;59:739-742.

KW - Graft-versus-tumour effect

KW - HSCT

KW - NK cells

KW - Neuroblastoma

UR - http://www.scopus.com/inward/record.url?scp=84864923799&partnerID=8YFLogxK

U2 - 10.1002/pbc.24030

DO - 10.1002/pbc.24030

M3 - Article

C2 - 22180305

AN - SCOPUS:84864923799

SN - 1545-5009

VL - 59

SP - 739

EP - 742

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

ER -